The bill titled 'S. 4840: A bill to expedite consideration of proposals for additions to, removals from, or other modifications with respect to entities on the Entity List' aims to streamline the process by which the U.S. government adds, removes, or modifies entities on the Entity List. The Entity List is a tool used by the Bureau of Industry and Security (BIS) to restrict the export, re-export, and transfer of certain items to entities that are deemed to pose a risk to national security or foreign policy interests. By expediting the consideration of proposals related to this list, the bill seeks to enhance the efficiency and responsiveness of the U.S. in addressing potential threats.
Supporters of the bill argue that it will strengthen national security by allowing for quicker action against entities that may pose risks. They believe that a more efficient process will enable the U.S. to better protect its interests and respond to emerging threats in a timely manner. Proponents also suggest that the bill demonstrates a commitment to maintaining robust export controls and safeguarding sensitive technologies.
Critics of the bill express concerns that expediting the process could lead to hasty decisions without thorough evaluation, potentially resulting in unjustified restrictions on entities. They worry that this could harm international relations and negatively impact businesses that rely on global supply chains. Opponents also caution that the bill might reduce transparency and limit opportunities for affected entities to appeal or provide input before being added to the Entity List.
While there are no direct industry overlaps between the bill's subject matter and the sponsor's top donor industries, the lobbying activity in this policy area raises some concerns. Notably, the American College of Clinical Pharmacy contributed $144,981, which indicates a vested interest in healthcare-related policies that could intersect with the bill's implications for entities on the Entity List. Additionally, Altria Client Services, a major player in the tobacco industry, has also invested $40,000, suggesting potential influence in regulatory matters that could affect their operations. Voters should be aware that while direct conflicts are not evident, the significant lobbying amounts could indicate a broader influence on the legislative process.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| AMERICAN COLLEGE OF CLINICAL PHARMACY | AMERICAN COLLEGE OF CLINICAL PHARMACY | $144,981 |
| ALTRIA CLIENT SERVICES | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | $40,000 |
| CROHN'S & COLITIS FOUNDATION | CROHN'S & COLITIS FOUNDATION | $40,000 |
| GOTRIANGLE | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | $30,000 |
| AFRICAN AMERICAN ALLIANCE OF CDFI CEOS | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | $20,000 |
| BRISTOL MYERS SQUIBB | ALEXANDER J. BECKLES, L.L.C. | $20,000 |
| CITY OF GLADEWATER, TEXAS | LONE STAR CONSULTING, LLC | $12,000 |
| CITY OF CRANDALL, TEXAS | LONE STAR CONSULTING, LLC | $10,000 |
| CITY OF JUSTIN, TEXAS | LONE STAR CONSULTING, LLC | $10,000 |
| THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES | MAGILL ASSOCIATES, LLC | undisclosed |
| OPPORTUNITIES INDUSTRIALIZATION CENTER OF AMERICA, INC. | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | undisclosed |
| LUMBEE TRIBE HOLDINGS, INC. | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | undisclosed |
| CITY OF CLEVELAND, TEXAS | LONE STAR CONSULTING, LLC | undisclosed |
| CITY OF RIO HONDO, TEXAS | LONE STAR CONSULTING, LLC | undisclosed |
| HOWARD COUNTY, TEXAS | LONE STAR CONSULTING, LLC | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Marsha Blackburn, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
